News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketScreener Nederland Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
New offering integrates virtual clinicians to create a scalable channel to increase availability of GeneDx exome testing for eligible children facing specialty-care barriers GAITHERSBURG, Md., August 11, 2026--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of …
In early August 2026, GeneDx Holdings Corp. reported second-quarter revenue of US$114.44 million with a net loss of US$17.74 million, reaffirmed its full-year 2026 revenue outlook, and announced a private placement of 81,967 Class A shares at US$61.00 each with participation from a Blackstone …
Faruqi & Faruqi, LLP is investigating potential claims against GeneDx Holdings Corp. (NASDAQ: WGS) and reminds investors of the August 3, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that GeneDx and its executives made …
GAITHERSBURG, Md., August 06, 2026--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences: Canaccord Genuity 46th Annual Growth Conference Boston, MA Fireside Chat: …
Analysts are showing increased optimism for GeneDx Holdings Corp. (NASDAQ:WGS) after its latest second-quarter results, which saw revenues beat expectations and statutory losses narrow more than anticipated. Although revenue forecasts remain unchanged for the coming year, analysts have revised their loss per share predictions, …
GeneDx Holdings Corp. (WGS) saw its stock climb 4.8% after reporting strong Q2 2026 results, with exome and genome revenue reaching US$100.3 million and a gross margin of around 70%. The company achieved adjusted profitability ahead of schedule, demonstrating its core engine's efficiency. However, …
This article first appeared on GuruFocus. Headline Earnings: Flat year on year, supported by improved NII growth of 4% and strong NIR growth of 10%. DHEPS Growth: Increased 2%, ahead of market expectations; excluding ETI base effects, DHEPS growth was very strong at 15%. …
This article first appeared on GuruFocus. Total Revenue: $114.4 million, up 11% year-over-year. Exome and Genome Revenue: $100.3 million, up 17% year-over-year. Exome and Genome Test Volume: 30,785 tests, up 32% year-over-year. Gross Margin: 70%, up sequentially from 69% in the first quarter. Adjusted …
Earnings Call Insights: GeneDx Holdings Corp. (WGS) Q2 2026 MANAGEMENT VIEW * “We hit a new record, resulting more than 30,000 exome and genome tests in the quarter, which represents 32% year-over-year growth. We reported $114.4 million of total revenue, exceeding our guide, and …
GeneDx Holdings Corp. (WGS) filed its quarterly earnings report (Form 10-Q) for the period ended June 30, 2026. The report details a new financing structure involving an amended loan agreement for an additional $50 million, increasing debt capacity to $150 million, and a conditional …
Reported second quarter 2026 revenue of $114.4 million, including $100.3 million in exome and genome revenue Reported exome and genome volume growth of 32% year-over-year Reported adjusted gross margin(1) of 70% and adjusted net income(1) of $0.4 million Reiterating full year 2026 revenue guidance …
Faruqi & Faruqi, LLP reminds investors of the August 3, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS). The lawsuit alleges that GeneDx and its executives made false and misleading statements regarding …
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of investors who purchased securities between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made materially false and misleading statements regarding …
The Rosen Law Firm is reminding investors who purchased common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025, and May 4, 2026, of the August 3, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that GeneDx made …
NEW YORK, Aug. 01, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”), of the important …
Kahn Swick & Foti, LLC (KSF) has reminded investors of GeneDx Holdings Corp. (NASDAQ: WGS) with substantial losses that they have until August 3, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that GeneDx and its executives …
Kahn Swick & Foti, LLC (KSF) is reminding investors in GeneDx Holdings Corp. (NasdaqGS: WGS) that they have until August 3, 2026, to apply for lead plaintiff in a securities class action lawsuit. The lawsuit alleges that GeneDx and its executives made false and …
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against GeneDx Holdings Corp. (NASDAQ:WGS) for alleged federal securities law violations. The lawsuit claims GeneDx made false and misleading statements about its business, leading to a significant drop in stock price after the …
Robbins Geller Rudman & Dowd LLP announces a lead plaintiff deadline of Monday, August 3, 2026, for investors who purchased GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made false or misleading …
A class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ:WGS) by Levi & Korsinsky, LLP, on behalf of investors who purchased securities between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx Holdings Corp. made false and misleading statements …
Levi & Korsinsky, LLP has issued a reminder to investors in GeneDx Holdings Corp. (NASDAQ: WGS) about a pending securities class action lawsuit. The lawsuit alleges that GeneDx management misled investors about deteriorating reimbursement rates and margin compression between April 16, 2025, and May …
Faruqi & Faruqi, LLP is reminding investors of the August 3, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS). The lawsuit alleges that GeneDx and its executives made misleading statements regarding the …
BlackRock, Inc. has filed a Schedule 13G disclosing a 5.5% beneficial ownership in GeneDx Holdings Corp. (WGS). The filing indicates BlackRock owns 1,622,518 shares of Class A stock, with sole voting power over 1,588,670 shares and sole dispositive power over all 1,622,518 shares. No …
Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS), urging investors with substantial losses to contact the firm before the August 3, 2026, lead plaintiff deadline. The lawsuit alleges GeneDx misled investors about the …
Search by ticker symbol or company name and select a result to open its chart.